{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T06:57:46Z","timestamp":1773212266295,"version":"3.50.1"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the efficacy, safety, and survival impacts of diverse induction chemotherapy regimens (including combination therapy with immune checkpoint inhibitors [ICIs]), radiotherapy modalities, and consolidation therapy in children, adolescents, and young adults (CAYA) with locally advanced or metastatic nasopharyngeal carcinoma (NPC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter retrospective study analyzed 102 CAYA NPC patients (aged 6\u201324 years; stage III\u2013IVB) from two Chinese centers (January 2011\u2013October 2024). All received induction therapy followed by concurrent chemoradiotherapy (CCRT), radiotherapy combined with concurrent anti-EGFR therapy, or radiotherapy alone, with select cases receiving consolidation (median follow-up: 22 months).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>GP and TPF induction achieved higher objective response rates (ORR) vs. TP (GP: 68.0% vs. TP: 31.6%, P = 0.005; TPF: 89.5% vs. TP: 68.0%, P &amp;lt; 0.001), though no significant difference in long-term survival was observed. ICIs + chemotherapy (n=15) improved ORR (93.3% vs. 53.3%, P = 0.013) though without a demonstrable difference in survival metrics at this follow-up. In patients achieving partial response (PR) post-induction, CCRT\/anti-EGFR therapy + radiotherapy improved 1-year progression-free survival (PFS: 94.5% vs. 50.0%, P &amp;lt; 0.001) and distant metastasis-free survival (DMFS: 97.4% vs. 50.0%, P &amp;lt; 0.001). For stable disease (SD) patients, multimodal therapy increased 5-year overall survival (OS: 100% vs. 66.7%, P = 0.046). Consolidation therapy (n=24) in locally advanced NPC was associated with clinical stage (P = 0.001) but not survival (P &amp;gt; 0.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>TPF\/GP regimens improved short-term responses with manageable toxicity. The addition of ICIs enhanced objective response rates, though survival benefits were not assessable within the limited follow-up period. CCRT demonstrated survival advantages over radiotherapy alone, especially in PR patients, while consolidation therapy showed limited benefit except in advanced subgroups. These findings, generated from a retrospective analysis, highlight the need for personalized strategies and warrant validation in larger prospective trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1765851","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T06:50:36Z","timestamp":1772175036000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["New insights into the treatment of nasopharyngeal carcinoma in children, adolescents, and young adults: a retrospective study"],"prefix":"10.3389","volume":"17","author":[{"given":"Mengwei","family":"Ren","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Tian","sequence":"additional","affiliation":[{"name":"Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology; National Key Discipline of Pediatrics (Capital Medical University); Key Laboratory of Major Diseases in Children, Ministry of Education; Beijing Children\u2019s Hospital, Capital Medical University, National Center for Children\u2019s Health","place":["Beijing, China"]},{"name":"Department of Pediatrics, Beijing Shijitan Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengyuan","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiran","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Runye","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Yuan","sequence":"additional","affiliation":[{"name":"Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology; National Key Discipline of Pediatrics (Capital Medical University); Key Laboratory of Major Diseases in Children, Ministry of Education; Beijing Children\u2019s Hospital, Capital Medical University, National Center for Children\u2019s Health","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junlin","family":"Yi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sidan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3390\/cancers10070210","article-title":"Genomic landscapes of EBV-associated nasopharyngeal carcinoma vs. HPV-associated head and neck cancer","volume":"10","author":"Ngan","year":"2018","journal-title":"Cancers (Basel)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.22521","article-title":"Differential features of nasopharyngeal carcinoma in children and adults: A SEER study","volume":"55","author":"Sultan","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26528","article-title":"A prospective protocol for nasopharyngeal carcinoma in children and adolescents: The italian rare tumors in pediatric age (TREP) project","volume":"118","author":"Casanova","year":"2012","journal-title":"Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11063","article-title":"Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: The dana farber cancer institute experience","volume":"97","author":"Haddad","year":"2003","journal-title":"Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905287","article-title":"Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma","volume":"381","author":"Zhang","year":"2019","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29795","article-title":"Proposal for the 8th edition of the AJCC\/UICC staging system for nasopharyngeal cancer in the era of intensity-modulated radiotherapy","volume":"122","author":"Pan","year":"2016","journal-title":"Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0125351","article-title":"Prognostic significance of tumor volume in locally recurrent nasopharyngeal carcinoma treated with salvage intensity-modulated radiotherapy","volume":"10","author":"Xiao","year":"2015","journal-title":"PLoS One"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.22465","article-title":"Immunotherapy for nasopharyngeal carcinoma: The earlier the better","volume":"330","author":"Bossi","year":"2023","journal-title":"JAMA"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.0388","article-title":"Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: An international, multicenter study of the mayo clinic phase 2 consortium (NCI-9742)","volume":"36","author":"Ma","year":"2018","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00594-4","article-title":"Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): A multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial","volume":"403","author":"Liu","year":"2024","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00106-023-01404-9","article-title":"Combination of nivolumab with standard induction chemotherapy in children and adults with EBV-positive nasopharyngeal carcinoma : Protocol of a prospective multicenter phase 2 trial","volume":"72","author":"R\u00f6mer","year":"2024","journal-title":"HNO"},{"key":"B14","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/cncr.11485","article-title":"Treatment outcome after radiotherapy alone for patients with stage I-II nasopharyngeal carcinoma","volume":"98","author":"Chua","year":"2003","journal-title":"Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s13014-014-0274-7","article-title":"Nasopharyngeal carcinoma in children and adolescents - a single institution experience of 158 patients","volume":"9","author":"Liu","year":"2014","journal-title":"Radiat Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ijrobp.2005.06.037","article-title":"Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients","volume":"64","author":"Baujat","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B17","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/cncr.25376","article-title":"Prognostic factors and long-term outcomes of childhood nasopharyngeal carcinoma","volume":"117","author":"Cheuk","year":"2011","journal-title":"Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20823","article-title":"Preradiation chemotherapy with methotrexate, cisplatin, 5-fluorouracil, and leucovorin for pediatric nasopharyngeal carcinoma","volume":"103","author":"Rodriguez-Galindo","year":"2005","journal-title":"Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27395","article-title":"Multimodal treatment, including interferon beta, of nasopharyngeal carcinoma in children and young adults: Preliminary results from the prospective, multicenter study NPC-2003-GPOH\/DCOG","volume":"118","author":"Buehrlen","year":"2012","journal-title":"Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21258","article-title":"Treatment of nasopharyngeal carcinoma in children and adolescents: Definitive results of a multicenter study (NPC-91-GPOH)","volume":"104","author":"Mertens","year":"2005","journal-title":"Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1055\/s-0041-111180","article-title":"Diagnosis and treatment of nasopharyngeal carcinoma in children and adolescents - recommendations of the GPOH-NPC study group","volume":"228","author":"Kontny","year":"2016","journal-title":"Klin Padiatr"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1575","article-title":"Gemcitabine and cisplatin regimen facilitates prognosis of advanced nasopharyngeal carcinoma","volume":"7","author":"Li","year":"2018","journal-title":"Cancer Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30410-7","article-title":"Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicentre, randomised controlled trial","volume":"17","author":"Sun","year":"2016","journal-title":"Lancet Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-015-2933-2","article-title":"International randomized phase 2 study on the addition of docetaxel to the combination of cisplatin and 5-fluorouracil in the induction treatment for nasopharyngeal carcinoma in children and adolescents","volume":"77","author":"Casanova","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"104779","DOI":"10.1016\/j.oraloncology.2020.104779","article-title":"Is nasopharyngeal carcinoma in young patients a distinct clinical entity? A single-institution case matched analysis in the era of intensity-modulated radiotherapy","volume":"107","author":"Ou","year":"2020","journal-title":"Oral Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01444-0","article-title":"Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: A multicenter randomized phase 3 trial","volume":"27","author":"Mai","year":"2021","journal-title":"Nat Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00302-8","article-title":"Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): A multicentre, randomised, double-blind, phase 3 trial","volume":"22","author":"Yang","year":"2021","journal-title":"Lancet Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ccell.2023.04.014","article-title":"Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)","volume":"41","author":"Yang","year":"2023","journal-title":"Cancer Cell"},{"key":"B29","doi-asserted-by":"publisher","first-page":"106218","DOI":"10.1016\/j.oraloncology.2022.106218","article-title":"Molecular characteristics of pediatric nasopharyngeal carcinoma using whole-exome sequencing","volume":"135","author":"Wu","year":"2022","journal-title":"Oral Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-019-01461-6","article-title":"Adapted strategy to tumor response in childhood nasopharyngeal carcinoma: The french experience","volume":"195","author":"Jouin","year":"2019","journal-title":"Strahlenther Onkol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000097","article-title":"Long-term outcomes following radiotherapy for adolescent patients with nonmetastatic WHO type III nasopharyngeal carcinoma","volume":"39","author":"Greenwalt","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70126-9","article-title":"Chemotherapy and radiotherapy in nasopharyngeal carcinoma: An update of the MAC-NPC meta-analysis","volume":"16","author":"Blanchard","year":"2015","journal-title":"Lancet Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.6552","article-title":"Induction chemotherapy followed by radiotherapy vs chemoradiotherapy in nasopharyngeal carcinoma: A randomized clinical trial","volume":"10","author":"Dai","year":"2024","journal-title":"JAMA Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.20181","article-title":"Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: The JUPITER-02 randomized clinical trial","volume":"330","author":"Mai","year":"2023","journal-title":"JAMA"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.4.1310","article-title":"Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized intergroup study 0099","volume":"16","author":"Al-Sarraf","year":"1998","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70320-5","article-title":"Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: A phase 3 multicentre randomised controlled trial","volume":"13","author":"Chen","year":"2012","journal-title":"Lancet Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"JCO2018777847","DOI":"10.1200\/JCO.2018.77.7847","article-title":"Analysis of plasma epstein-barr virus DNA in nasopharyngeal cancer after chemoradiation to identify high-risk patients for adjuvant chemotherapy: A randomized controlled trial","author":"Chan","year":"2018","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01123-5","article-title":"Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial","volume":"398","author":"Chen","year":"2021","journal-title":"Lancet"}],"updated-by":[{"DOI":"10.3389\/fimmu.2026.1821175","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1765851\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T09:15:00Z","timestamp":1773134100000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1765851\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2026.1765851"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1765851","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"article-number":"1765851"}}